Decisive early decisions compound value, while delayed decisions compound risk. Rather than waiting for Phase 3 results to determine access viability, advanced modeling approaches such as MBMA and QSP, enable HEOR teams to inform go/no-go decisions and Phase 3 study design earlier, when development and access strategies remain adaptable.

This webinar focuses on how advanced modeling can support high-impact, Phase 3–critical decisions, helping teams reduce uncertainty, align evidence generation with payer expectations, and improve the likelihood of reimbursement success.